Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 8/20 | 0.71 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.71 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.71 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.71 |
| ▸ | CA1 | P00915 | 2/20 | 0.71 |
| ▸ | CA2 | P00918 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | FAAH | O00519 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.71 |
| ▸ | HTR2C | P28335 | 1/20 | 0.71 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.71 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.71 |
| ▸ | HTR2B | P41595 | 1/20 | 0.71 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL249198 | 1.00 | GABRA1 (0.71) | GABRA1GABRB1GABRB2TSHRGABRG2 | |
| SCHEMBL249795 | 1.00 | GABRA1 (0.71) | GABRA1GABRB1GABRB2TSHRGABRG2 | |
| SCHEMBL560318 | 0.94 | TSHR (0.68) | GABRA1GABRB1GABRB2TSHRGABRG2 | |
| SCHEMBL560346 | 0.94 | TSHR (0.68) | GABRA1GABRB1GABRB2TSHRGABRG2 | |
| SCHEMBL202738 | 0.94 | TSHR (0.68) | GABRA1GABRB1GABRB2TSHRGABRG2 | |
| SCHEMBL561299 | 0.94 | TSHR (0.68) | GABRA1GABRB1GABRB2TSHRGABRG2 | |
| Hydrochloric Acid SCHEMBL7076051 | 0.91 | TSHR (0.65) | GABRA1GABRB1GABRB2TSHRGABRG2 | |
| Hydrochloric Acid SCHEMBL6039756 | 0.89 | TSHR (0.63) | GABRA1GABRB1GABRB2TSHRGABRG2 | |
| SCHEMBL21767240 | 0.87 | TSHR (0.54) | GABRA1GABRB1GABRB2TSHRGABRG2 | |
| SCHEMBL9167214 | 0.85 | GABRA1 (0.74) | GABRA1GABRB1GABRB2TSHRGABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306598-A2 | SCHIFF BASE OLIGOMERS | The Boeing Company (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2021178738-A1 | SCHIFF BASE OLIGOMERS | THE BOEING COMPANY (US) | 2021-09-10 | — | — | WO | disclosed |
| CN-108558685-B | 2, 6-disubstituted phenol meglumine derivative and application thereof | 西安力邦制药有限公司 | 2020-11-20 | — | — | CN | disclosed |
| CN-108558685-A | 2,6- disubstituted benzenes phenol meglumine analog derivative and application | 西安力邦制药有限公司 | 2018-09-21 | — | — | CN | disclosed |
| US-20160367442-A1 | ORAL DRUG DELIVERY DEVICE AND METHODS OF USING THE SAME | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2016-12-22 | — | — | US | disclosed |
| US-20130217783-A1 | Therapeutic Compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217783-A1 | Therapeutic Compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217783-A1 | Therapeutic Compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8350097-B2 | Therapeutic compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8350097-B2 | Therapeutic compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2392559-A1 | Therapeutic compounds | Pharmacofore, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20100249246-A1 | Therapeutic Compounds | PHARMACOFORE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249246-A1 | Therapeutic Compounds | PHARMACOFORE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249246-A1 | Therapeutic Compounds | PHARMACOFORE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| CN-101687746-A | therapeutic compounds | PHARMACOFORE INC | 2010-03-31 | — | — | CN | disclosed |
| EP-2152651-A1 | THERAPEUTIC COMPOUNDS | Pharmacofore, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008141099-A1 | THERAPEUTIC COMPOUNDS | PHARMACOFORE, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008141099-A1 | THERAPEUTIC COMPOUNDS | PHARMACOFORE, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-4628127-A | Heterogeneous catalytic alkylation | ETHYL CORPORATION (US) | 1986-12-09 | — | — | US | disclosed |
| US-3933927-A | Phenol transalkylation process | ETHYL CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217783-A1 | Therapeutic Compounds | OPRM1, OGFR, UGT1A1 | GABRA1 202/4885GABRB1 189/4885GABRB2 262/4885 |
| US-20100249246-A1 | Therapeutic Compounds | OPRM1, OGFR, UGT1A1 | GABRA1 202/4885GABRB1 189/4885GABRB2 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.